The impact of different antiretroviral agents on the risk of developing or surviving CNS disease remains unknown. The aim of this study was to investigate whether using antiretroviral regimens with higher CNS penetration effectiveness (CPE) scores was associated with reduced incidence of CNS disease and improved survival in the UK Collaborative HIV Cohort (CHIC) Study.
has recently been proposed as a method of estimating the CNS penetration of antiretrovirals. 7 Based upon pharmacokinetic data, results of clinical studies, and drug properties, antiretrovirals are each assigned a score (with higher scores estimating better penetration). Studies have shown that using regimens with higher CPE scores is associated with an increased probability of achieving undetectable CSF HIV-1 RNA levels, 8 improved neuropsychological performance, 8, 9 and longer survival. 10 In contrast, worse neurocognitive performance was described in a recent, prospective study in subjects receiving regimens with higher CPE scores. 11 Finally, although currently unpublished, data have reported better survival following PML, HIVe, cryptococcal meningitis (CRYPTO), and cerebral toxoplasmosis (TOXO) when antiretroviral regimens with higher CPE scores were used. 12, 13 The aim of this study was to investigate whether the use of cART with higher CPE scores is associated with reduced incidence of CNS diseases and improved survival within a large UK cohort between 1996 and 2008.
METHODS Standard protocol approvals, registrations, and patient consents. The UK Collaborative HIV Cohort (CHIC) Study is an observational cohort study currently involving 12 of the largest UK HIV clinical centers (appendix). Ethical approval was granted via the National Research Ethics Service (West Midlands MREC, UK), reference number MREC/00/7/47. According to UK regulation, individual written consent was not required from patients as only anonymized data routinely collected for other purposes were used.
Subject identification. Eligible subjects for this work were
HIV-1-infected adults (over 16 years old) who started cART at any date between January 1, 1996, and December 31, 2008, and with at least 1 day of follow-up data after starting cART available for analysis. Data including risk group for HIV acquisition, antiretroviral exposure, laboratory test results, AIDS diagnoses, and deaths were collected. CNS opportunistic diseases (CNS events) included any first report of a clinical diagnosis of HIVe, PML, TOXO, or CRYPTO occurring after commencing cART. Subjects experiencing a CNS event prior to commencing cART were excluded, thus all reported events in this series occurred in subjects who were cART experienced.
cART was defined as any antiretroviral regimen containing a protease inhibitor, non-nucleoside reverse transcriptase inhibitor, abacavir, or an integrase/entry inhibitor, regardless of number of drugs in the combination (thus permitting protease inhibitor monotherapy and some triple nucleoside regimens to be included). cART regimens were then scored using the CPE system and each individual's CPE score was updated each time a drug in the regimen was changed. According to Letendre et al., 14 each antiretroviral drug was given a CPE score between 1 (low CNS penetration) and 4 (high CNS penetration) and a regimen total calculated.
Statistical analysis. Demographic characteristics and clinical
parameters were stratified according to the CPE score of the initial cART regimen (categorized as Յ4, 5-7, 8 -9, and Ն10). Independent associations between clinical factors and an initial CPE score of Յ4 were investigated using multivariable logistic regression analysis, utilizing a backwards selection process. Factors considered for these analyses were gender and mode of HIV transmission (categorized as men having sex with men, female heterosexuals, male heterosexuals, injection drug use, male other/unknown, female other/unknown), ethnicity (white, black African, other/unknown), age, CD4 count, HIV RNA, treatment status (antiretroviral-naïve or experienced), and calendar year at cART initiation.
The incidence of a first CNS event (overall and stratified by CPE score) was calculated by dividing the number of events occurring by the total person-years of follow-up (PYFU) in the cohort. For these analyses, patient follow-up started on the date of cART initiation and ended on the date of the patient's first CNS event. For those who remained free of CNS events at the end of the study period, follow-up was right-censored at the earliest of death, December 31, 2008, or 3 months after the patient's last clinic visit. Poisson regression models were used to describe any association between the CPE score and the development of each event, after adjustment for potential confounding factors. Two sets of analyses were performed: the first considered baseline covariates only (CPE score of initial regimen, sex/mode of transmission, age, ethnicity, CD4 count, HIV RNA, treatment status, and calendar year at cART initiation), whereas the second incorporated changes in several of these covariates over time (latest CPE score, CD4 count, and HIV RNA) through the use of time-dependent covariates-this latter model also incorporated a time-dependent covariate for time since initiation of cART.
Similar analyses were performed for all-cause mortality; for these analyses, patient follow-up started on the date of cART initiation and ended at the earliest of death, December 31, 2008, or 3 months after the patient's last clinic visit. All statistical analyses were performed using SAS v 9.1 software. p Values below 0.05 were considered significant.
RESULTS
Over the study period, 22,356 subjects with no history of prior CNS events commenced cART. Median (interquartile range [IQR]) duration of follow-up of patients after starting cART was 4.6 (1.9 -8.5) years (118,123 PYFU in total), with 89.4% of this follow-up time being spent on cART, 1.1% on non-cART regimens, and 9.5% off treatment. Median (IQR) age at cART initiation was 36 (31-42) years, 16,704 (75%) of subjects were male, and 5,864 (26%) were of black African ethnicity (table 1). At the time of commencing cART, median (IQR) plasma CD4ϩ lymphocyte count and plasma HIV RNA were 200 (100 -300) IU/mL and 4.8 (4.0 -5.3) log 10 copies/mL, respectively. Over the study period, median (IQR) CPE score for initial cART regimen initially increased from 7 (5) (6) (7) (8) in 1996/1997 to 9 (8 -10) in 2000/2001 and subse-quently declined to 6 (7-8) in 2006/2008. The majority of subjects (79.8%) were commenced on an initial cART regimen with a CPE score of 5-9. Differences in gender, HIV risk group, and ethnicity existed between CPE score strata. For instance, subjects with a baseline CPE score of Յ4 tended to be older, had lower plasma CD4ϩ cell counts, and were less likely to be treatment-naïve than those with higher baseline CPE scores.
Multivariable logistic regression analyses revealed that subjects who initiated cART while antiretroviralnaïve and those with a higher CD4 count were less likely to be prescribed an initial regimen with a low CPE score, whereas those of other or unknown ethnici-ties, older subjects, and those who initiated cART from 1996 to 1999 or from 2004 onwards were more likely to be prescribed an initial regimen with a low CPE score (table 2) .
Development of CNS events during study period.
In total, 251 subjects experienced a new CNS event during the study period (HIVe: 80; TOXO: 59; CRYPTO: 56; PML: 54) over a total of 113,633 PYFU (censored at first event). Kaplan-Meier estimates of the proportions experiencing a CNS event by 1, 2, 3, 4, and 5 years after initiation of cART were 0.6%, 0.8%, 1.0%, 1.1%, and 1.2%, respectively. The overall CNS event rate after starting Table 1 Baseline characteristics of patients included in the study, overall and stratified by CNS penetration effectiveness (CPE) score of initial combination antiretroviral therapy (cART) When stratified according to the initial CPE score, CNS event rates were highest in those subjects prescribed regimens with CPE scores of Յ4 and were lowest in subjects prescribed regimens with CPE scores of Ն10 (figure), although these differences were nonsignificant, both before and after adjust-ment for potential confounders (table 3) . When considering baseline covariates only, predictors of a new CNS event were heterosexual transmission, older age, a lower pretreatment CD4 count or higher plasma HIV RNA, and prior exposure to mono-or dual-NRTI therapy before starting cART. When we considered changes in the CPE score over time, a CPE score of Յ4 again appeared to be associated with an increased risk of a new CNS event. However, as with the baseline analysis, this association did not remain significant after adjustment for potential confounders. Similar associations were found between heterosexual transmission, older age, lower CD4 count, and higher plasma HIV RNA and the risk of a new CNS event, as with the baseline analysis. Time since initiation of cART was additionally identified as a strong predictor of a new CNS event in these analyses, with the event rate being particularly high in the first 6 months. After controlling for this covariate, prior NRTI exposure was no longer associated with an increased risk of a new CNS event.
Mortality. During the study period, 1,581 subjects died, giving an overall all-cause mortality rate of 13.8/1,000 PYFU. After stratifying according to the CPE score of the initial regimen, mortality was highest in those who were prescribed regimens with CPE scores Յ4 (21.0 deaths/1,000 PYFU) and dropped as the CPE score increased (table 4) . Similarly, after stratification by most recent CPE score, rates of death were highest in those with a CPE score Յ4 (16.5 deaths/1,000 PYFU) and again dropped as the CPE score increased. A CPE score Յ4, whether based on the initial or latest cART regimen, was strongly associated with an increased mortality risk, although both associations were generally attenuated after adjustment for potential confounders. Of note, patients who had discontinued antiretroviral treatment had the highest mortality risk in time-updated analyses, supporting the hypothesis that treatment may have been selectively discontinued in those at terminal stages of disease.
DISCUSSION
The relationship between antiretroviral CNS penetration and HIV-related CNS disease is of clinical importance, and may influence future antiretroviral selection in HIV-1-infected subjects.
In this large cohort study, we have retrospectively assessed the relationship between CPE score of different cART regimens and the incidence of CNS events and survival. Several interesting observations were made. First, significant changes in the median CPE score of initial cART have occurred between 1996 and 2008. This is likely to reflect changes in prescribing trends (represented in treatment guidelines) as clinical evidence and newly licensed antiretrovirals became available. Interestingly, there has been an overall reduction in CPE score in the most recent years studied. While the majority of individuals achieving full suppression of HIV replication in plasma will achieve similar results in CSF and respond clinically, 15 it is possible that a trend toward lower CPE scores may, in the future, increase the risk of HIV replication in the CNS compartment, resulting in more cerebral sequelae, including cognitive problems and HIV-associated encephalopathy.
We also observed a significant association between initial cART CPE score and subject demographics (gender, HIV risk group), calendar year of treatment initiation, and clinical parameters (including CD4 cell count and plasma HIV RNA). This novel finding suggests that, according to a subject's clinical status, treatment is tailored or individualized, particularly in those with advanced HIV disease or previous poor adherence. Such individuals in this cohort were more likely to be prescribed regimens with very low (Յ4) CPE scores. To our knowledge, this association has not previously been reported and may reflect a subgroup of individuals with high levels of comorbidity or opportunistic disease. Such confounders are important considerations when the CPE score is utilized as a research tool in retrospective analyses, as bias in outcome data would be expected. Abbreviations: cART ϭ combination antiretroviral therapy; CPE ϭ CNS penetration effectiveness rank; IDU ϭ injection drug use; MSM ϭ men having sex with men; NA ϭ not available. We observed low rates of CNS events overall in this cohort, with low plasma CD4ϩ cell count, high plasma HIV RNA, and short time elapsed since cART initiation all significantly associated with increased event risk, rather than CPE score. This suggests that strategies to support adherence to effective therapies, particularly in early months of treatment, are more important than selection of neuropenetrative antiretroviral agents. Unfortunately, adherence data are not collected within this cohort study and therefore this important factor could not be further evaluated. Interestingly, however, a proportion of subjects did experience CNS events while plasma HIV RNA was fully suppressed. In these subjects it is possible viral replication within the CNS compartment and modest CPE score of cART (median 7) may have influenced the pathogenesis of these events; however, due to small numbers, it is not possible to draw further conclusions.
In this cohort, we observed an independent association between lower CPE scores (initial and most recent) and higher all-cause mortality, after adjustment for relevant clinical factors. This finding may reflect the process of altering cART due to a subject's clinical parameters (as earlier described) with those deteriorating clinically or with advanced disease being prescribed regimens with lower scores than asymptomatic individuals. Alternatively, it may be hypothesized that an association between low CPE score and poorer survival (despite the absence of relationship with our selected CNS events) is in fact related to cognitive impairment (for which no data were collected) occurring on cART regimens with low neuropenetration. Cognitive impairment has previously been associated with increased mortality in HIV-1-infected adults 16, 17 and improved survival outcomes in perinatally infected adolescents with higher CPE scoring regimens have also been reported. 10 However, without randomized, prospective data, this explanation remains speculative.
Limitations of our cohort data include the absence of information regarding immune reconstitution syndrome, adherence, and clinic attendance. Furthermore, all CNS events were reports of clinical diagnoses rather than strict protocol-defined criteria, and data regarding cognitive impairment are not collected. Reporting of events may therefore have varied by clinician, center, and over the study period. While the study size is large, CNS events occur relatively infrequently, limiting our power to perform more detailed analyses. Finally, analyses of the changing CPE score over time may be affected by time-varying confounding, in that treatments may be selectively switched in those already showing early signs of CNS problems; thus, it is difficult to assess the causal asso-ciation between regimens with different CPE scores and the development of these events. While novel statistical methods exist for the evaluation of causal effects (subject to the assumption of no unmeasured confounding), their application requires large study sizes. As such, collaborative efforts are ongoing between several large HIV cohorts to apply these methods to this question, with results anticipated within the next 1-2 years. Nevertheless, this study adds important information to our understanding of the relationship between CPE score, CNS events, and survival. We highlight, in particular, that clinical status at time of commencing cART influences antiretroviral selection and CPE score. This should be considered when utilizing CPE scores for retrospective cohort analyses.
